KPTI - KPTI Stock Climbs Following $150 Million USD Royalty Agreement

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has announced that it is entering a royalty agreement with HealthCare Royalty Partners, boosting KPTI stock.

Karyopharm, a Massachusettes-based pharmaceutical firm, will receive an initial $75 million USD by the end of this month for HCR, and an additional $75 million USD  once certain regulatory and commercial milestones have been reached. In return, HCR will receive a tiered royalty in the mid-single digits based on worldwide net revenues of Xpovio and any other future products. Xpovio is a product currently being developed by Kyropharm, which can be used to treat patients with ...